Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities
NEW YORK, April 18, 2024 /PRNewswire/ -- Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities.
- NEW YORK, April 18, 2024 /PRNewswire/ -- Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities.
- The New York-based firm will only focus on enhancing and expanding its nicotine replacement therapy (NRT) products, specifically TBX-FREE™ and TBX VAPE-FREE™.
- "Given the alarming data linking e-cigarette use to serious health risks, Redwood is committed to advancing our development of TBX-FREE™ and TBX VAPE-FREE™ products," said Jason Cardiff, CEO of Redwood Scientific Technologies.
- Redwood believes that its TBX-FREE™ and TBX VAPE-FREE™ products will be innovative solutions in the realm of nicotine replacement therapy.